Altimmune (ALT)
NASDAQ:ALT
Want to see ALT full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.27Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed significant progress: strong financing ($225M offering; $535M pro forma cash), regulatory recognition (Breakthrough Therapy), alignment with FDA/EMA on the PERFORMA Phase III protocol, robust Phase II efficacy/tolerability signals, and near-term readouts (AUD topline; RESTORE enrollment). Challenges were mostly operational and expected for a late-stage biotech: higher G&A and R&D as programs advance, a wider net loss in the quarter, ongoing validation/integration of digital pathology tools, and a competitive landscape necessitating clear differentiation. Overall, the positives — especially the cash runway and Phase III readiness — materially outweigh the manageable execution and competitive risks.Company Guidance
Completed Oversubscribed Financing
Closed an oversubscribed public offering in April with $225.0M gross proceeds; pro forma cash of ~$535.0M as of April 30 (up from $332.0M at March 31, a ~61% increase), providing runway through the pro forma Phase III MASH 52-week data readout expected in 2029.
Advance to Late-Stage Development — PERFORMA Phase III
Finalized Phase III (PERFORMA) protocol for MASH, submitted to FDA and aligned with EMA; CRO partner engaged and global start-up activities underway with study initiation planned for H2 2026.
Regulatory Recognition — Breakthrough Therapy Designation
Pemvidutide received FDA Breakthrough Therapy Designation in MASH, underscoring regulatory recognition of potential clinical benefit.
Strong Phase II Efficacy and Tolerability Signals
Phase II IMPACT showed strong efficacy at 24 and 48 weeks, particularly at 1.8 mg; low discontinuation rates (fewer AE-related discontinuations in pemvidutide arms versus placebo) and improved adherence reported; 2.4 mg to be introduced in Phase III based on additional weight-loss signal.
Scientific Validation at EASL
48-week Phase II IMPACT results selected as an oral 'Best of EASL' presentation; additional posters planned (cardiovascular risk factors, weight loss, NIT, Q-fibrosis), increasing scientific visibility and KOL engagement ahead of Phase III.
Multiple Near-Term Clinical Milestones
Topline data from the Phase II RECLAIM trial in Alcohol Use Disorder expected next quarter (Q3 2026 referenced as 'next quarter' in call); RESTORE (ALD) enrollment expected to complete in Q3 2026.
Focused Clinical & Operational Execution
Company has strengthened executive team and prioritizes execution for Phase III start-up, global site activation, clinical supply chain readiness and CRO collaboration.
Detailed R&D Spending on Pemvidutide
Q1 2026 R&D expense of $16.2M included $9.5M of direct pemvidutide development costs (MASH $3.7M; AUD/ALD $4.2M; CMC $1.6M), indicating continued investment in core programs.
ALT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $3.08 | $3.02 | -1.95% |
Mar 05, 2026 | $4.27 | $3.50 | -17.92% |
Nov 06, 2025 | $3.75 | $3.94 | +5.07% |
Aug 12, 2025 | $3.38 | $3.62 | +7.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Altimmune (ALT) report earnings?
Altimmune (ALT) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Altimmune (ALT) earnings time?
Altimmune (ALT) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALT EPS forecast?
ALT EPS forecast for the fiscal quarter 2026 (Q2) is -0.15.